Navigation Links
Neptune Krill Oil, NKO(R), enters WALGREENS, the largest U.S. retail pharmacy chain, under the brand name Schiff(R) MegaRed(TM)
Date:9/15/2008

use capacity expansion program and by also partnering with a strategic industrial manufacturing company within the short term for substantial additional capacity," added Mr. Thierry Houillon.

NKO(R) is a proprietary phospholipid omega-3 composition extracted from Antarctic Krill and patented for its extraction process, composition and for its medicinal use. NKO(R)'s safety and health benefits have been demonstrated by clinical studies in hyperlipidemia (high cholesterol), premenstrual syndroms, inflammation and arthritic disease. The development of several functional food product lines as well as pharmaceutical product opportunities for three pharmaceutical markets including the over-the-counter, the prescription medical food and prescription drug market are currently underway.

About Neptune

Neptune researches and develops proprietary bioactive ingredients and products for nutraceutical and pharmaceutical applications and is carrying out clinical research to show the therapeutic benefits in various medical indications. The Company patents and protects its innovations and continuously expands its intellectual property portfolio. Neptune has already obtained many regulatory approvals allowing commercialization of its products in various geographic markets and has filed for and is expecting additional approvals. Neptune continues to strongly support its strategic development plan to form partnership with worldwide leaders in the nutraceutical industries. Neptune signed agreements with Nestle and Yoplait, worldwide leading food manufacturers, and paved its entrance into the global functional food market.

Neither NASDAQ nor TSX Venture Exchange accepts responsibility for the

adequacy or accuracy of this press release.

(1) Walgreens at http://www.walgreens.com

Statements in this press release that are not statements of historical or current fact constitute "forward-lookin
'/>"/>

SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
2. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
3. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
4. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
5. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
6. Neptune Technologies receives GRAS notification in the United States
7. Neptune Technologies expands into medicinal markets in Asia Pacific
8. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
9. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
10. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
11. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Earlier this year in a June 24 international ... Adult Stem Cell Technology Center, LLC ( ASCTC ) ... unique property of adult tissue stem cells. His ... the Past, Important for the Future,” embodied the essence ... the address at the 4th World Congress on Cell ...
(Date:12/24/2014)... December 23, 2014 According to Ross Selinger, ... Affiliate of ITRA Global, the national office market continues to ... This is evidenced by the third quarter’s surprising 3.9% ... Low energy costs have held inflation down and the ... is the housing market remaining soft. , This solid economic ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... at 19.7% by 2019. It also provides a carefully ... strategies and challenges for the market. , Full Copy ... the report, the global market for cell expansion will ... future. It expects this growth to be driven by ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... , ... ... ... ...
... , ... symposium to unveil study aimed at ensuring global food security and sustainability. , ... Washington (PRWEB) -- On ... sustainably double agricultural output and improve storage and distribution to eliminate the global productivity ...
... ... ... ... ...
Cached Biology Technology:Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 2Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 3Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 4Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 5Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 6Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 7Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 8Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 9Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 10Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 11Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 12Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 13Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 14Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 15Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 16Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 17Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 18Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 19Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 20Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 21Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 22Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 23Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 24Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 25Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 26Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 27Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 28Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 29Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 30Gloabl Harvest Initiative: Taking Down Fences To Meet Future Needs 2Gloabl Harvest Initiative: Taking Down Fences To Meet Future Needs 3Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9 2Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9 3Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9 4Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9 5
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... physics now becomes easier with the formal launch of ... from the American Physical Society. Physics will highlight and ... publications of Physical Review Letters and the ... will keep readers apprised of important new articles as ...
... information, as detectives, historians and identity thieves well ... treasures, University of Delaware researchers have found. ... UD,s Delaware Biotechnology Institute analyzed the cellular waste ... discovered formerly hidden relationships between genes and the ...
... of Oregon,s Climate Leadership Initiative, the need to address ... Bob Doppelt says in his new book requires a ... The 240-page book published by London-based Earthscan Publications Ltd. ... private sector, but its content is accessible to "anyone ...
Cached Biology News:American Physical Society announces Physics, a new, free, online publication 2Using novel tool, UD researchers dig through cell 'trash' and find treasure 2Using novel tool, UD researchers dig through cell 'trash' and find treasure 3'No time to lose' to start thinking sustainability 2
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
... CellBIND surface is produced by a ... more hydrophilic surface giving more consistent, ... and yields. CellBIND enhances cell attachment ... reduced serum or serum-free medium. • ...
Cell Culture Flask, 75 cm, treated polystyrene...
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
Biology Products: